Información del artículo
El Texto completo está disponible en PDF
Bibliografía
[1.]
J. Hays, J.K. Okene, R.L. Brunner, J.N. Kotchen, J.E. Manson, R.E. Patterson, et al.
Women's Health Initiative Investigators. Effects of estrogen plus progestin on health-related quality of life.
N Engl J Med, 348 (2003), pp. 1835-1837
[2.]
WHI.
Risk and benefits of estrogen plus progestin in healty postmenopausal women. Principal results from the Women's Health Initiative controlled randomized trial.
JAMA, 288 (2002), pp. 321-333
[3.]
WHI.
Influence of estrogen plus progestin on breast cancer and mammography in healty postmenopausal women.
JAMA, 289 (2003), pp. 3243-3253
[4.]
C. Magnuson, J.A. Baron, N. Correia, R. Bergstrom, H.O. Adami, I. Person.
Breast cancer risk following long-term oestrogen and oestrogen-progestin replacement therapy.
Intern J Cancer, 81 (1999), pp. 339-344
[5.]
C. Sschairer, J. Lubin, R. Troisi, S. Sturgeon, R. Brinton, R. Hoover.
Menopausal estrogen and estrogen-progestin replacement therapy and breast cancer risk.
JAMA, 283 (2000), pp. 485-491
[6.]
T. Cornwell, W. Cohick, I. Raskin.
Dietary phytoestrogens and health.
Phytochemistry, 65 (2004), pp. 995-1016
[7.]
J.E. Manson, J. Hsia, K.C. Johnson, J.E. Rossouw, A.R. Assaf, N.R. Lasser, et al.
The Women's Health lnitiative lnvestigators. Estrogen plus progestin and the risk of coronary heart disease.
N Engl J Med, 349 (2003), pp. 523-534
[8.]
C. Castelo-Branco, J.E. Blümel, J. Haya, L. Binfa, S. Sarra.
Impacto del estudio WHI en pacientes y medicos.
Toko-Gin Práct, 62 (2003), pp. 200-205
[9.]
J. Calaf, M. Ferrer.
Tratamiento farmacológico de la menopausia en España en 2002.
Clin Invest Gin Obst, 30 (2003), pp. 299-306
[10.]
L.A. Fitzpatrick.
Soy isoflavones: hope or hype?.
Maturitas, 44 (2003), pp. 21-29
[11.]
D.I. Rowland, M. Faughnan, C. Hoey, K. Wahala, G. Williamson, A. Cassidy.
Bioavailability of phyto-oestrogens.
Br J Nutr, 89 (2003), pp. 45-58
[12.]
K.D. Setchell, E. Lydeking-Olsen.
Dietary phytoestrogens and their effect on bone: evidence from in vitro and in vivo, human observational, and dietary intervention studies.
Amer J Clin Nutr, 78 (2003), pp. 593-609
[13.]
E. Krebs, K.E. Ensrud, R. MacDonald, T.J. Wilt.
Phytoestrogens for treatment of menopausal symptoms: a systematic review.
Obstet Gynecol, 104 (2004), pp. 824-836
[14.]
R. Sánchez-Borrego, M. Ribes-Redondo, M. Cuadros Vilá.
Fitoestrógenos. Tipos. Mecanismos de acción.
Fitoestrógenos, pp. 9-28
[15.]
NIH.
Inventory of Clinical Trials.
National Institutes of Health, (1975),
[16.]
Editorial.
Clin Invest Gin Obst., 30 (2003), pp. 77
[17.]
X. Bonfill.
Els assaigs clínics, entre el gra i la palla.
Annals de Medicina, 87 (2004), pp. 97
[18.]
X. Carné, J.A. Arnaiz.
Els assaigs clínics, entre la investigació i el marketing.
Annals de Medicina, 87 (2004), pp. 98-100
[19.]
G. Urrutia.
Els assaigs clínics i els motius.
Annals de Medicina, 87 (2004), pp. 101-103
[20.]
P. Hernando.
Una perspectiva des de la bioètica.
Annals de Medicina, 87 (2004), pp. 107-108
[21.]
C. Vallvé.
L’assaig clínic i els prescriptors.
Annals de Medicina, 87 (2004), pp. 109-111
[22.]
F. Naftolin, M.G. Stanbury.
Phytoestrogens: are they really estrogen mimics?.
Fertil Steril, 77 (2002), pp. 15-17
[23.]
C. Adams, S. Cannell.
Women's beliefs about «natural» hormones and natural hormone replacement therapy.
Menopause, 8 (2001), pp. 433-440
[24.]
L.A. Fitzpatrick.
Soy isoflavones: hope or hype?.
Maturitas, 44 (2003), pp. 21-29
[25.]
K.D.R. Setchell, H. Adler Creutz.
Mammalian lignans and phytoestrogens. Recent studies on their formation, metabolism, and biological role in health and disease.
Role of the gut flora in toxicity and cancer, pp. 315-345
[26.]
D.C. Knight, J.A. Eden.
A review of the clinical effects of phytoestrogens.
Obst Gynecol, 87 (1996), pp. 897-904
[27.]
S. Watanabe, M. Yamaguchi, T. Sobue, T. Takahashi, T. Mihura.
Pharmacokinetics of soybeans isoflavones in plasma, urine and faeces of men after ingestion of 60 g. baked soy bean powder (Kinako).
J Nutr, 128 (1998), pp. 1710-1715
[28.]
L.J. Lu, S.N. Lin, N. Grady, N. Nagaman, K.E. Andersen.
Altered kinetics, of urinary daidzein ans genistein excretion in women during chronic soya exposure.
Nutr Cancer, 26 (1996), pp. 289-302
[29.]
F. Naftolin, M.G. Stanbury.
Phytoestrogens: are they really estrogen mimics?.
Fertil Steril, 77 (2002), pp. 15-17
[30.]
J.A. Tice, B. Ettinger, K. Ensrud, R. Wallace, T. Blackwell, S.R. Cummings.
Phytoestrogens supplements for the treatment of hot flashes: the isoflavone clover extract (ICE) study: a randomized controlled trial.
JAMA, 290 (2003), pp. 207-214
[31.]
S. Washbum, G.L. Burke, T. Morgan, M. Anthony.
Effect of soy protein supplementation on serum lipoproteins, blood pressure, and menopausal symptoms in perimenopausal women.
Menopause, 6 (1999), pp. 7-13
[32.]
D. Kotsopoulos, F.S. Dalais, Y.L. Lyang, B.P. McGrath, I.D. Teede.
The effects of soy protein containing phytoestrogens on menopausal symptoms in postmenopausal women.
Climateric, 3 (2000), pp. 161-167
[33.]
S.K. Quella, C.L. Loprinzi, D.L. Barton, A. Knost l, A. Sloan l, B.I. La Vasseur, et al.
Evaluation of soy phytoestrogens for the treatment of hot flashes in breast cancer survivors: a North Central Cancer Treatment Group Trial.
J Clin Oncol, 18 (2000), pp. 1068-1074
[34.]
G. Scambia, D. Mango, P.G. Signorice, R.A. Anselmi Angeli, C. Palena, D. Gallo, et al.
Clinical effects of a standardized soy extract in postmenopausal women: a pilot study.
Menopause, 7 (2000), pp. 105-111
[35.]
S. Carranza-Lira, O.F. Barahona, D. Ramos, L. Herrera, A. Olivares-Segura, G. Cardoso, et al.
Changes in symptoms, lipid and hormone levels after the administration of a cream with phytoestrogens in the climateric: preliminary report.
Int J Fertil Women Med, 46 (2001), pp. 296-299
[36.]
H.J. Teede, F.S. Dalais, D. Kotsopoulos, Y-L. Liang, S. Davis, B.P. McGrath.
Dietary soy has both beneficial and potencially adverse cardiovascular effects: a placebo-controlled study in men and postmenopausal women.
J Clin Endocrinol Metab, 86 (2001), pp. 3053-3060
[37.]
V. Jayagopal, P. Albertazzi, E.S. Kilpatrick, E.M. Howarth, F.E. Jennings, D.A. Hepburn, et al.
Beneficial effects of soy phytoestrogen intake in postmenopausal women with type 2 diabetes.
Diabetes Care, 25 (2002), pp. 1709-1714
[38.]
A. Lemay, S. Dodin, N. Kadri, H. Jacques, J.C. Forest.
Flaxseed dietary supplement versus hormone replacement therapy in hypercholesterolemic menopausal women.
Obstet Gynecol, 100 (2002), pp. 495-504
[39.]
E.A. Lucas, R.D. Wild, L.J. Hammond, D.A. Khalil, S. Juma, B.P. Daggy, et al.
Flaxseed improves lipid profile without altering biomarkers of bone metabolism in postmenopausal women.
J Clin Endocrinol Metab, 87 (2002), pp. 1527-1532
[40.]
L.A. Simons, M. Von Konigsmark, J. Simons, D.S. Celermager.
Phytoestrogens do not influence lipoprotein levels or endothelial function in healthy postmenopausal women.
Am J Cardiol, 85 (2000), pp. 1297-1301
[41.]
A. Dewell, B. Hollenbeck Clarie, B. Bruce.
The effects of soy-derived phytoestrogens on serum lipids and lipoproteins in moderately hypercholesterolemic postmenopausal women.
J Clin Endocrinol Metab, 87 (2002), pp. 118-121
[42.]
M.J.J. De Kleijn, Y.T. Van der Schow, P.W.F. Wilson, D.E. Grobbee, P.F. Jacques.
Dietary intake of phytoestrogens is associated with a favorable metabolic cardiovascular risk profile in postmenopausal US women: the Framingham Study.
J Nutr, 132 (2002), pp. 276-282
[43.]
D.L. Alekel, A.S. Germain, C.T. Peterson, K.B. Hanson, J.N. Stewart, T. Toda.
Isoflavone-rich soy protein isolate attenuates bone loss in the lumbar spine in the perimenopausal women.
Am J Clin Nutr, 72 (2000), pp. 844-852
[44.]
S.C. HO, S.G. Chan, Q. Yi, E. Wong, P.C. Leung.
Soy intake and the maintenance of peak bone mass in Hong Kong Chinese women.
J Bone Miner Res, 16 (2001), pp. 1363-1369
[45.]
J. Mei, S.S. Yeung, A.W. Kung.
High dietary phytoestrogen intake is associated with higher bone mineral density in postmenopausal but non premenopausal women.
J Clin Endocrinol Metab, 86 (2001), pp. 5217-5221
[46.]
C.M. Chiechi, G. Secreto, M. D’Amore, M. Fanelli, E. Venturelli, F. Cantatore, et al.
Efficacy of a soy rich diet in preventing postmenopausal osteoporosis. The Memphis randomized trial.
Maturitas, 42 (2002), pp. 295-300
[47.]
M.K. Kim, B.C. Chung, V.Y. Yu, J.H. Nam, H.C. Lee, K.B. Huh, et al.
Relationships of urinary phyto-estrogens excretion to BMD in postmenopausal women.
Clin Endocrinol (Oxf), 56 (2002), pp. 321-328
[48.]
N. Morabito, A. Crisafulli, C. Vergara, A. Gaudio, A. Lasco, N. Frisina, et al.
Effects of genistein and hormone-replacement therapy on bone loss in early postmenopausal women: a randomized double-blind placebo controlled study.
Bone Miner Res, 17 (2002), pp. 1904-1912
[49.]
P.B. Clifton-Bligh, R.J. Baber, J.R. Fulcher, M.L. Nery, T. Moreton.
The effect of isoflavones extracted from red clover (Rimostil) on lipid and baile metabolism.
Menopause, 8 (2001), pp. 259-265
[50.]
P. Alexandersen, A. Toussaint, C. Christiansen, J.P. Devogelaer, C. Roux, J. Fechtenbaum, et al.
Ipriflavone Multicenter European Fracture Study. Ipriflavone in the treatment of postmenopausal osteoporosis: a controlled trial.
JAMA, 285 (2001), pp. 1482-1488
[51.]
D.L. Alekel, A.S. Germain, C.T. Petersen, K.B. Hanson, J.W. Stewart, T. Toda.
Isoflavone rich soy protein isolate attenuates bone loss in the lumbar spine of perimenopausal women.
Am J Clin Nutr, 72 (2000), pp. 844-852
[52.]
E. Burdette, J. Liu, D. Lantvit, E. Lim, H.N. Booth.
Trifolium pratense (red clover) exhibits estrogenic effects in vivo in ovariectomized Spragne-Dawley rats.
J Nutr, 132 (2002), pp. 27-30
[53.]
E. Rodríguez Bueno, F. Baro.
Novedades del tratamiento de la osteoporosis.
Folia Clin Intern, 49 (2005), pp. 65-69
[54.]
G. Scambia, D. Mango, P.G. Signorile, R.A. Angelli, C. Palena.
Clinical effects of standardized soy extract in postmenopausal women: a pilot study.
Menopause, 7 (2000), pp. 105-111
[55.]
M. Manubens Grau.
Acción de los fitoestrógenos sobre los cánceres.
Fitoestrógenos, pp. 67-76
[56.]
W. Wuttke, H. Jarry, T. Becker, A. Schultens, V. Christoffel, Ch. Gorkow, et al.
Phytoestrogens: endocrine disrupters or replacement for barman replacement therapy?.
Maturitas, 44 (2003), pp. 9-20
[57.]
C.H. Wood, Th.C. Register, M.S. Anthony, N.D. Kock, J. Mark Cline.
Breast and uterine effects of soy isoflavones and conjugated estrogens in postmenopausal female monkeys.
J Clin Endocrinol Metab, 89 (2004), pp. 3462-3468
[58.]
L.M. Chiechi, G. Putignano, V. Guerra, M.P. Schiavelli, A.M. Cisternino, C. Carriero.
The effect of a soy rich diet on the vaginal epithelium in postmenopause: a randomized double blind clinical trial.
Maturitas, 45 (2003), pp. 241-246
[59.]
P. Diez, K. Smolnikar, T. Schultz, U. Laudenbach-Leschowski.
Phytoestrogens and carcinogenesis–Differential effects of genistein in experimental models of normal and malignant rat endometrium.
Hum Reprod, 16 (2001), pp. 997-1006
[60.]
P.L. Horn-Ross, K.J. Hoggatt, D.W. West, M.R. Krone, S.L. Stewart, H. Anton, et al.
Recent diet and breast cancer risk: the California Teachers Study (USA) [citado en 16].
Cancer Causes Control, 13 (2002), pp. 407-415
[61.]
Q. Dai, A.A. Franke, F. Jin, X.O. Shu, I.R. Hebert, L.J. Custer, et al.
Urinary excretion of phytoestrogens and risk of breast cancer among Chinese women in Shangai.
Cancer Epidemiol Biom Prev, 11 (2002), pp. 815-821
[62.]
A. Kilkkinen, J. Virtamo, E. Vartiainen, R. Sankila, R.J. Virtanen, H. Aldercreutz, et al.
Serum enterolactone concentration is not associated with breast cancer risk in a nested casecontrol study.
Int J Cancer, 108 (2004), pp. 277-280
Copyright © 2005. Elsevier España S.L.. Todos los derechos reservados
